The VXX exchange-traded note, which aims to track futures on the CBOE Volatility Index, has more than $1bn of investors’ cash.
But if you put $100 in at the beginning,
you’d struggle to pay for a round of cappucinos
with what’s left. That’s why the
wires have been humming with bile about the product.
Theo Casey dons his judge’s wig and tries
to give it a fair trial.
There’s no prize for the most optimistically
marketed and overbought financial products, but perhaps there
should be. Perhaps the awards could be known as the Hypers.
A retrospective adjudication might come up with:
2007 Icelandic bank bonds
2008 Lehman Brothers Guaranteed Mini Note
2009 United States Oil Fund ETF
Among the pile of nominees for the 2010 Hyper, otherwise
known as the Golden Raspberry, is Barclays
Capital’s iPath S&P 500 Vix Short-Term Futures
ETN – the VXX.
This article is available to subscribers and registered users
Please log in to continue reading.
Not yet registered? Take a free trial.
If you have already taken a free trial you
have ongoing access to the analysis section of FOW.com including this story.
Log in using your details below to read.
Already have an account? |